SAN DIEGO—Oncology nurses can implement simple measures to ensure the safe disposal of cytotoxic therapies, according to Baltimore researchers.
The measures are aimed at reducing the hazards posed by chemotherapy disposal to neighboring communities and the environment.
According to standard policy at most cancer centers, chemo therapy waste is collected in designated yellow plastic containers, which are disposed of as regulated medical waste and incinerated,
SAN DIEGO—Creative strategies used by local chapters of the Oncology Nursing Society (ONS) to recruit and retain members and reach out to their local communities were described in poster presentations at the 2010 Congress. Using these strategies, the chapters not only increased membership but also strengthened ties with their communities.
San Diego ONS chapter meets goal of 210 by 2010
SAN DIEGO—Oncology nurses who work in an adult community–based practice can remain abreast of new information provided that a range of options for continuing education (CE) is available, according to a new study.
CHICAGO—Cancer patients and survivors should strive to get 150 minutes per week of moderate-intensity aerobic exercise, according to new national guidelines. That is the same recommendation for the general public.
Although the evidence indicates that most types of physical activity, from swimming to yoga to strength training, are beneficial for cancer patients, the guidelines say clinicians should tailor exercise recommendations to individual patients.
CHICAGO—A risk stratification schema can be used to identify older patients who are at risk of grade 3 to 5 toxicity from chemotherapy. The schema includes risk factors based on cancer type, patient age, upfront dose of chemotherapy, the chemotherapeutic regimen used, and history of falling, among others, said Arti Hurria, MD.
“We wanted to develop a predictive model for tolerance to therapy in older adults with cancer,” she said.
CHICAGO—Cabazitaxel is the first treatment to show a survival benefit in patients with metastatic castration-resistant prostate cancer (mCRPC), according to data from a phase 3 trial.
On June 17, cabazitaxel became the first drug approved by the US Food and Drug Administration (FDA) for the treatment of hormone-refractory prostate cancer. Results from the phase 3 trial delivered at ASCO were included in the FDA review.
CHICAGO—Among patients with chronic myeloid leukemia (CML) in the Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed Patients (ENESTnd) study, major molecular response (MMR) rates with nilotinib remain superior to those with imatinib after follow-up extended to a median of 18.5 months. Read More ›
To sign up for our newsletter or print publications, please enter your contact information below.
